Metabolic · In Clinical Trials
Mazdutide
No lawful US pathway
01 · Overview
Mazdutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist given as a once-weekly subcutaneous peptide injection. By co-activating both receptors, it aims to combine the glucose-lowering and weight-reducing effects of GLP-1 with the energy-expenditure and hepatic actions of glucagon receptor stimulation.
It is developed by Innovent Biologics and Eli Lilly and is not FDA-approved, but was approved in China in 2025 for weight management and later for type 2 diabetes (PMID 41028652).
02 · Research summary & key findings
In the phase 3 GLORY-1 trial in Chinese adults with obesity or overweight, mean weight change at 48 weeks was -11.0 to -14.0 percent with mazdutide versus 0.3 percent with placebo, with mostly mild to moderate gastrointestinal adverse events (PMID 40421736). A US phase 2 trial in adults with obesity or overweight without diabetes reported weight reductions of 7.3 to 18.1 percent at 32 weeks versus 0.9 percent with placebo (PMID 42628555). It is also under clinical evaluation for metabolic dysfunction-associated fatty liver disease, obstructive sleep apnea, and alcohol use disorder (PMID 41028652).
03 · Regulatory status
Mazdutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Mazdutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Mazdutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight N Engl J Med, 2025. PMID 40421736
- [2]Mazdutide: First Approval Drugs, 2025. PMID 41028652
- [3]Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial Lancet Diabetes Endocrinol, 2026. PMID 42628555
Primary literature
- PubMed: "Mazdutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Mazdutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Mazdutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.